文献速递前列腺癌

Gleason分级分组2前列腺癌的主动监测:当代欧洲队列的肿瘤学结局

Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort.
PubMed 文献 · Eur Urol Oncol · 2025-02-18

这项多中心研究纳入2016至2024年间法国、西班牙、意大利、瑞士和德国十家中心接受主动监测的139例Gleason分级分组2前列腺癌患者,基线MRI显示81例(59%)存在PI-RADS 4-5分病灶,中位随访38个月,3年无转移生存率为98.1%,56例接受根治性治疗,26例重新分级为分级分组3,结论认为在活检前MRI和影像引导活检时代,主动监测是经选择分级分组2患者的可选管理方式。

要点

  • 139例分级分组2患者接受主动监测,3年无转移生存率98.1%(95%CI 95.5-100%)。
  • 随访期间56例接受根治性治疗,26例重新分级为分级分组3。
  • 28例根治性前列腺切除标本中13例(46%)见不良病理特征,仅2例(7%)为极具侵袭性疾病。

核心结论

  • 在活检前MRI和影像引导活检时代,主动监测是经选择的分级分组2前列腺癌患者的一种可选管理方式。
  • 未来研究应聚焦于重新定义靶向活检时代的主动监测纳入标准,因为许多分级分组2患者远处进展的绝对风险较低。

研究设计与样本

  • 多中心研究,纳入2016年至2024年间法国、西班牙、意大利、瑞士和德国十家参考中心接受主动监测的分级分组2前列腺癌患者。
  • 排除被认为不适合根治性治疗(即观察等待)的患者。
  • 主要终点为无转移生存。
  • 共纳入139例分级分组2前列腺癌患者。

主要发现

  • 基线MRI显示81例(59%)存在前列腺影像报告和数据系统评分4-5分的病灶。
  • 中位无事件随访38个月(四分位距20-63)。
  • 观察到2例转移,无前列腺癌死亡。
  • 估计3年无转移生存率为98.1%(95%置信区间95.5-100%)。
  • 随访期间56例接受根治性治疗,26例重新分级为分级分组3前列腺癌;28例接受根治性前列腺切除术者中,最终病理显示不良特征(分级分组3和/或pT3a)13例(46%),极具侵袭性疾病(分级分组≥4和/或≥pT3b和/或pN1)仅2例(7%)。

关键数值与推荐

  • 是否符合欧洲泌尿外科学会主动监测纳入标准的两组之间结局无统计学显著差异(所有log-rank检验p>0.05)。

临床怎么用

  • 作者认为,在活检前MRI和影像引导活检时代,主动监测是经选择的分级分组2前列腺癌患者的一种可选管理方式。
  • 作者建议未来研究应聚焦于重新定义靶向活检时代的主动监测纳入标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Uptake of active surveillance for patients with Gleason grade group (GG) 2 prostate cancer (PCa) remains low. Magnetic resonance imaging (MRI) before biopsy would allow better patient selection, but there are no published data on this strategy. Our aim was to report one of the first European AS series of patients with GG 2 PCa selected via MRI before image-guided biopsy. METHODS: This multicenter study enrolled patients with GG 2 PCa managed with AS between 2016 and 2024 in ten reference centers in France, Spain, Italy, Switzerland, and Germany. Patients deemed unsuitable for curative treatment (ie, watchful waiting) were excluded. The primary endpoint was metastasis-free survival. KEY FINDINGS AND LIMITATIONS: A total of 139 patients with GG 2 PCa were included. Baseline MRI revealed a lesion with a Prostate Imaging-Reporting and Data System score of 4-5 in 81 patients (59%). Median event-free follow-up was 38 mo (interquartile range 20-63). Two cases of metastasis were observed, and there were no deaths due to PCa. The estimated 3-yr metastasis-free survival rate was 98.1% (95% confidence interval 95.5-100%). Overall, 56 patients underwent definitive treatment and 26 were reclassified as having GG 3 PCa during follow-up. Among the 28 patients who underwent radical prostatectomy, final pathology revealed adverse features (GG 3 and/or pT3a) in 13 cases (46%), but very aggressive disease (GG ≥4 and/or ≥pT3b and/or pN1) was noted in only two cases (7%). There were no statistically significant differences in outcomes between groups that did and did not meet the European Association of Urology inclusion criteria for AS (all log-rank tests p > 0.05). CONCLUSIONS AND CLINICAL IMPLICATIONS: In the era of prebiopsy MRI and image-guided biopsy, AS is a safe management option for selected patients with GG 2 PCa. Future studies should focus on redefining current inclusion criteria for AS in the targeted biopsy era, as many patients with GG 2 PCa are at low absolute risk of distant progression.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Baboudjian M, Leni R, Oderda M, et al. Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. Eur Urol Oncol. 2025. PMID: 39965999. doi:10.1016/j.euo.2025.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。